Travere Therapeutics
NEWS
These prices refer to the company’s list price. Most patients will not pay that price because of various forms of health insurance or patient assistance programs.
These are the top biotech companies headquartered in Biotech Beach based on 2018 revenue. Here’s the brief information including the revenue of each company.
Retrophin, Inc. announced the appointment of Peter Heerma as chief commercial officer, effective immediately.
Retrophin, Inc. announced that Eric Dube, Ph.D., chief executive officer, will present at the 2019 Cantor Global Healthcare Conference in New York City on Thursday, October 3, 2019 at 5:20 p.m. ET.
Retrophin, Inc. announced that the Phase 3 FORT Study evaluating the safety and efficacy of fosmetpantotenate compared to placebo in patients with pantothenate kinase-associated neurodegeneration did not meet its primary endpoint and did not demonstrate a difference between treatment groups.
Biopharma companies large and small are involved in numerous clinical trials. Here’s a look at some of the top stories from last week.
Shares of Retrophin have plunged more than 24% in premarket trading after the San Diego-based company announced its Phase III treatment for pantothenate kinase-associated neurodegeneration did not stack up against placebo.
Retrophin, Inc. reported its second quarter 2019 financial results and provided a corporate update.
Retrophin, Inc. announced that Eric Dube, Ph.D., chief executive officer, will present at the Canaccord Genuity 39th Annual Growth Conference in Boston on Wednesday, August 7, 2019 at 8:30 a.m. ET.
JOBS
IN THE PRESS